Midsize pharmaceutical companies are the industry’s big deal makers this year, replacing larger brethren as new sources of capital emerge. Typically the biggest drugmakers do the most deals by value. Yet large-cap pharmaceutical companies have pulled back on acquisitions this year, as they pay down debt from previous sprees and resist high premiums.
Trending:
Midsize pharmaceutical firms are the industry's big deal makers this year